Anders Waas
Chairman of the Board
Anders Waas, born 1957, is the Chairman of Sobrera Pharma since 2019. Waas has more than 35 years of experience with senior positions the pharmaceutical, biotechnology and med-tech industry. He has held senior global positions in business and product development. He has a background as head of business development in AstraZeneca, Actogenics and CV Therapeutics and most recently as CEO at TikoMed. As previously Vice President Business Development for CV Therapeutics, USA, he has many years of commercial and business development experience from the US market. Waas is currently Business Development Director at GUV, Gothenburg.
Ulf Johnsson
Board member
Ulf Jonsson, born 1949, is a board member in Sobrera Pharma since 2019. Jonsson, has 40 years of experience from the pharmaceutical industry, primarily within AstraZeneca. He has held senior, global positions covering areas such as pharmacokinetics, drug delivery, product development, portfolio management and business development. Ulf has extensive experience and knowledge of business development and negotiations in the pharma field and in the design and development of oral extended release formulations.
Elin Löf
Board member
Elin Löf, born in 1974, has more than 10 years of experience with product development from the pharmaceutical industry, across psychiatry and neurology portfolios. She currently holds a position as Director and Head of Medical Strategy and Communication within neurology at H Lundbeck A/S headquarters in Denmark. Löf further has experience with research in the area of Alcohol Use Disorder from the Sahlgrenska Academy, University of Gothenburg where she did her PhD and Postdoc.
Anders Milton
Board member
Anders Milton, born 1947, board member since 2020. Milton MD., PhD., has extensive experience in board work and a national and international network in healthcare, industry and among investors. Currently, Milton is Chairman of Vironova, Immune System Regulation,Stiftelsen Europaskolan i Strängnäs, Stiftelsen Motivationslyftet, and a member of several boards. Milton has previously served as Chairman of the Medical Assoc., SACO, Swedish Red Cross, People and Defense, and the World Medical Assoc. Milton has also been investigator of Swedish HIV & AIDS policy, Swedish psychiatry, donation and organ transplantation, and unwanted pregnancies, as well as a member of the Disaster Commission after the 2004 tsunami.
Bo Söderpalm
Board member
Bo Söderpalm, born 1959, is a board member in Sobrera Pharma since 2019. Söderpalm, M.D., Ph.D., is Professor and Chief physician at the Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, University of Gothenburg. He is the Co-Founder of Sobrera Pharma. Söderpalm is an experienced senior researcher and clinician since 30 years and has performed several clinical studies in the area of alcohol abuse.
Marcus Trummer
Board member
Marcus Trummer, born 1980, is a board member in Sobrera Pharma since 2022. Trummer has extensive experience in board work, most recently with Byggmästare Anders J Ahlström Holding AB, an investment company working hands as an active investor. Trummer has over 15 years experience from working as board director, investing and strategy development.
Tomas Bergström
Board alternate
Tomas Bergström, born 1971, is a boardmember in Sobrera Pharma since 2023. He has more than 20 years’ experience of, investments, strategic business development and operational assignments in a leading position. Previously, he was Senior Vice President at OptiGroup and CEO of Textilia as well as a partner in Erneholm Haskel and Associate at Enskilda Securities, among other things. Bergström is currently the CEO of Byggmästare Anders J Ahlström Holding AB.
Andrea de Bejczy
Board alternate
Andrea de Bejczy, M.D., Ph.D., at the Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, University of Gothenburg is the Co-Founder of Sobrera Pharma. She is an experienced researcher and clinician and has performed several clinical studies in the area of alcohol abuse.
Klementina Österberg
Board alternate
CEO of GU Ventures and chair of GOKAP. Expert at building new companies. Experienced board member in the life science sector including Ectin Research AB, Aprit Biotech AB, Cereno Scientific AB, Texray AB, OnDosis AB, Iscaff Pharma AB, OligoNova Accelerate AB and Toleranzia AB.